Friday, May 9, 2025
5/9/2025
Characterization of ApoE4 Induced Phospholipid Dysregulation in AD Pathogenesis - PROJECT SUMMARY APOE4 is the strongest genetic risk factor for sporadic AD with Ab-dependent and Ab-independent effects on disease pathogenesis. However, the molecular mechanisms underlying the pathogenic nature of APOE4 are not fully elucidated. In previous funding period, we have demonstrated that APOE4-induced phosphoinositol biphosphate (PIP2) dyshomeostasis through the increased expression of a PIP2-degrading enzyme, synaptojanin 1 (synj1). In parallel, a non-biased multiscale network analysis of human dataset from the AMP-AD consortium identifies synj1 as a key driver in both male and female AD subnetworks. Synj1 reduction has been found to provide several beneficial effects such as rescuing APOE4-associated cognitive impairments and lysosomal defects. Notably, we discovered that APOE4+ microglia have higher synj1 expression at baseline, and that APOE4+ microglia manifests with impaired phagocytic activities and lysosomal defects when compared to APOE3+ microglia which can be rescued by synj1 haploinsufficiency. A pilot study indicates that lowering synj1 expression in E4FAD mice protects against cuprizone-induced chronic neuro-inflammation and cognitive/motor deficits in vivo. We postulate that the APOE-synj1-PIP2 signal pathway plays a functional role in regulating microglial function, and that dysregulated microglial synj1-PIP2 homeostasis induced by APOE4 may lead to dysregulated immune function and excessive synaptic elimination, promoting APOE4-associated neuroinflammation and synaptic dysfunction. Therefore, we will characterize the regulation of microglial function by the APOE-synj1-PIP2 signaling pathway during aging and AD pathogenesis in this renewal application. We propose to 1) investigate microglial synj1 function in modulating APOE4-regulated neuroinflammation in AD in vivo (Aim 1) using cuprizone-induced inflammation in male and female EFAD mouse models (human ApoE4 knock-in at 5xFAD background); 2) to characterize the molecular mechanisms by which the APOE-synj1-PIP2 signaling pathway regulates microglial function (Aim 2) using mouse microglia from EFAD mice (synj1+/+ and synj1+/-), mouse microglia from TREM2-/- or APOE-/- mice, and human iPSC-derived microglia from APOE3+/+ and APOE4+/+ normal and AD subjects; 3) to investigate temporal and spatial relationship between dysregulated microglial function and excessive neurite and synaptic elimination using ex vivo 3-D co-culture of iPSC-derived brain cells; 4) to perform high resolution multiscale network modeling using scRNA-seq dataset from mouse brains and RNA-seq dataset from human iPSC-derived microglia and co-culture to identify microglia-specific molecular signatures driven by APOE-synj1-PIP2 signaling; and 5) to validate identified molecular signature in post-mortem human brain samples (Aim 3). The goals of this application aim to elucidate novel pathways and molecular signatures underlying APOE4-induced microglial dysfunction. These studies will facilitate identification and development of a more personalized targeted therapy to APOE-regulated neuroinflammation in AD.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).